Message sent to Consillium8 Jan 2021 07:13
Dear Sir/Madam,
As an investor in SNG, myself and a number of other investors are concerned about the lack of information provided by the company at present. While we understand staff at Synairgen will be incredibly busy - there is a great deal of uncertainty regarding progress of the Phase 3 trial - which was said would start in Q4 2020.
It would be good to update investors on progress on this front and also progress on the home trial.
With announcements from the government yesterday about new COVID drugs, there is a worry that Synairgen will be left behind - without regular PR and communications with investors and the wider medical community, reminding them that SNG is one of the more promising drugs being trialled. Any communication may at the same time serve to promote the home trial - where I gather take-up has been slow.
While it is pleasing that vaccines and alternative drugs are becoming available to help solve this crisis - we have invested in Synairgen as we believe it will prove to be one of the best options out there, and we are keen that it fulfills its potential, and does not get overlooked.
I expect the usual bland response from Consillium, as I appreciate you cannot give out any market sensitive information - however, I would appreciate that in your next conversation with Synairgen, you pass on the sentiment about increasing the level of PR at this crucial stage.
Kind regards,
Xxxx